Phathom Pharmaceuticals, Inc. Free Cash Flow

Free Cash Flow of PHAT for past 10 years: annual, quarterly and twelve month trailing (TTM) including Free Cash Flow growth rates and interactive chart. Free cash flowis calculated as operating cash flow minus of capital expenditures. Interest payments are excluded from the generally accepted definition of free cash flow. Free cash flow is the cash flow available to all the investors in a company, including common stockholders, preferred shareholders, and lenders. Some investors prefer FCF or FCF per share over earnings and earnings per share as a measure of profitability. However, because FCF accounts for investments in property, plant, and equipment it can be lumpy over time. Free cash flow is usually used in discounted cash flow models to determine a company's intrinsic value.

Highlights and Quick Summary

  • Free Cash Flow for the quarter ending June 29, 2021 was $-28.4 Million (a -43.11% decrease compared to previous quarter)
  • Year-over-year quarterly Free Cash Flow increased by 35.86%
  • Annual Free Cash Flow for 2020 was $-70.5 Million (a 14.09% increase from previous year)
  • Annual Free Cash Flow for 2019 was $-61.8 Million (a 5942.13% increase from previous year)
  • Twelve month Free Cash Flow ending June 29, 2021 was $-127 Million (a 17.54% increase compared to previous quarter)
  • Twelve month trailing Free Cash Flow increased by 93.3% year-over-year
Trailing Free Cash Flow for the last four month:
29 Jun '21 30 Mar '21 30 Dec '20 29 Sep '20
$-127 Million $-108 Million $-70.5 Million $-65.9 Million
Visit for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow statement with 10 years of data, and state-of-the-art screener.

Historical Free Cash Flow of Phathom Pharmaceuticals, Inc.

Most recent Free Cash Flowof PHAT including historical data for past 10 years.

Interactive Chart of Free Cash Flow of Phathom Pharmaceuticals, Inc.

Phathom Pharmaceuticals, Inc. Free Cash Flow for the past 10 Years (both Annual and Quarterly)

(All values are in $ million)

Year Q1 Q2 Q3 Q4 Fiscal Year
2021 $-28.41 $-49.93
2020 $-28.12 $-20.91 $-9.4 $-12.09 $-70.52
2019 $-23.49 $-7.13 $-30.33 $-0.81 $-61.81
2018 $-0.3 $-0.72 $-1.02

Business Profile of Phathom Pharmaceuticals, Inc.

Sector: Healthcare
Industry: Biotechnology
Phathom Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. The company has the rights in the United States, Europe, and Canada to vonoprazan, a potassium-competitive acid blocker (P-CAB) that blocks acid secretion in the stomach. It is also developing vonoprazan, which is in Phase III clinical trials for the treatment of erosive gastroesophageal reflux disease; and in combination with antibiotics for the treatment of Helicobacter pylori infection. The company was incorporated in 2018 and is headquartered in Florham Park, New Jersey.